000			03703nam a22003735i 4500
999			_c80393 _d80393 _x1
001			80393
003			ES-MaUEC
005			20230207040303.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			140405s2014 gw | s |||| 0|eng d
020			_a9783319042206
024	7		_a10.1007/978-3-319-04220-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC262 _b2014 EB
245	0	0	_aInfectious Complications in Cancer Patients _cedited by Valentina Stosor, Teresa R. Zembower
264		1	_aCham, Switzerland _bSpringer _c2014
300			_a1 recurso en línea (X, 511 p.) _b18 ilustraciones, 13 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Treatment and Research _x0927-3042 _v161
505	0		_aHost impairments in patients with neo plastic diseases -- Epidemiology of Infections in Cancer Patients -- Bacterial Pathogens -- Fungal Infections in Cancer Patients -- Advances in the Management of Viral Infections -- Neutropenic Fever and Sepsis:Â{u5DA1}aluation and Management -- Respiratory Infections -- Enteric Infections -- Central Nervous System Infections in Cancer Patients and Hematopoietic Stem Cell Transplant Recipients -- Dermatologic infections in cancer patients.-Â{u9BA6}fections in Patients with Leukemia and Lymphoma -- Infectious Complications of Stem Cell Transplantation -- Infections Associated with Solid Malignancies -- Antimicrobial Agents, Drug Adverse Reactions and Interactions and the Cancer Population -- Infection Control and Prevention Considerations -- Prevention of Infection in Cancer Patients.
520			_aWhile advances in both the treatment of cancer and the management of its complications have led to significant improvement in patient survival, infections remain a significant cause of morbidity and mortality in patients with neoplastic disease. In this patient population, infection risk results from a complex interplay between the hostâ€{u3835}nderlying immunodeficiencies, local tumor effects, and treatment-induced immunosuppression. New chemotherapeutic approaches and antimicrobial prophylaxis and treatment practices continue to shape the spectrum of infections in these patients. Clinicians who treat infections in cancer patients are continually challenged by the emergence of new pathogens and by the increasing antimicrobial resistance of established ones. The aim of this book, is to emphasize unique aspects of management of infectious diseases in the cancer patient. With the increasing complexity of this patient population, optimal management requires a multidisciplinary approach, and this fact is fully reflected in the contributions, all from recognized authorities in the field. Ultimately, it is hoped that this volume will assist specialists in infectious diseases and haematology/oncology in the diagnosis, management, and prevention of infection and optimization of the overall care of patients with malignancies.
988			_aEBOOK, EBSPRINGER
650		7	_9170148 _aCáncer _2embne _xComplicaciones
700	1		_aStosor, Valentina _eeditor literario _988518 _0Local
700	1		_aZembower, Teresa R _eeditor literario _988519 _0Local
710	2		_aSpringerLink (Online service) _0Local _9106996
830		0	_aCancer Treatment and Research _x0927-3042 _v161 _9133669 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-04220-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b10/2020 _dz _eIG _feng _ggw _h0